Effects of Eicosapentaenoic Acid on the Glycerophosphate Shuttle‐Regulated Inflammatory and Thermogenic Responses
Obesity · 2026
DOI: 10.1002/oby.70053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, 2026. Verfasst von Yujiao Zu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Texas Tech University, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Eicosapentaenoic Acid, Thermogenesis, Glycerolphosphate Dehydrogenase, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NCCIH NIH HHS, Texas Tech University, College of Health & Human Sciences, department of Nutritional Sciences and the Obesity Research Institute, Office of Research & Innovati…, Texas Tech University.
Abstract (Originalsprache)
Objective
Mitochondrial glycerol‐3‐phosphate dehydrogenase (GPD2) is a crucial enzyme in the glycerophosphate shuttle, linking glycolysis, lipogenesis, and oxidative phosphorylation, making it a potential target for obesity treatment. Given the metabolic benefits of eicosapentaenoic acid (EPA), an omega‐3 polyunsaturated fatty acid, we hypothesized that EPA modulates the GPD2‐centered glycerophosphate shuttle to reduce adiposity, glucose intolerance, and inflammation while increasing energy expenditure.
Methods
Male and female GPD2 knockout (KO) and wild‐type (WT) littermates were fed a high‐fat diet (HF) without or with an 18 g EPA/kg (EPA) diet for 13 weeks. Body weight, glucose tolerance, and metabolic profiles were assessed, and blood and tissues were collected following euthanasia.
Results
Male GPD2 KO mice exhibited reduced adiposity and lower lipid accumulation in hepatic and adipose tissues compared to WT males. These effects were linked to lipid metabolism and beige fat activation. EPA supplementation reduced body weight and promoted glucose clearance in both WT and KO males, with enhanced hepatic lipid oxidation. However, GPD2 deficiency and EPA had minimal metabolic effects in females.
Conclusions
Our findings highlight potential mechanisms by which GPD2 combats obesity by mediating lipid metabolism. Our findings further demonstrate the sex‐dependent nature of EPA's metabolic benefits, independent of GPD2 deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences, Texas Tech University, Lubbock, Texas, USA.
- Institute for One Health Innovation & Center of Excellence in Obesity and Cardiometabolic Research, Texas Tech University & Texas Tech Health Sciences Center, Lubbock, Texas, USA.
- Department of Mechanical Engineering, Texas Tech University, Lubbock, Texas, USA.
- Department of Physics and Astronomy, Texas Tech University, Lubbock, Texas, USA.
- Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
- School of Veterinary Medicine, Texas Tech University, Amarillo, Texas, USA.
ORCID-Profile: Hanna Moussa, William T Festuccia, Naima Moustaid-Moussa
Förderung
- NCCIH NIH HHS
- Texas Tech University, College of Health & Human Sciences, department of Nutritional Sciences and the Obesity Research Institute, Office of Research & Innovati…
- Texas Tech University
Zitieren
APA
Zu, Y., Mikhael, M., Andrade, J., Scoggin, S., Yosofvand, M., Moussa, H., Festuccia, W. T., & Moustaid-Moussa, N. (2026). Effects of Eicosapentaenoic Acid on the Glycerophosphate Shuttle‐Regulated Inflammatory and Thermogenic Responses. Obesity. https://doi.org/10.1002/oby.70053
Vancouver
Zu Y, Mikhael M, Andrade J, Scoggin S, Yosofvand M, Moussa H, et al. Effects of Eicosapentaenoic Acid on the Glycerophosphate Shuttle‐Regulated Inflammatory and Thermogenic Responses. Obesity. 2026. doi:10.1002/oby.70053
BibTeX
@article{Zu2026,
author = {Zu, Yujiao and Mikhael, Mark and Andrade, Jose and Scoggin, Shane and Yosofvand, Mohammad and Moussa, Hanna and Festuccia, William T and Moustaid-Moussa, Naima},
title = {Effects of Eicosapentaenoic Acid on the Glycerophosphate Shuttle‐Regulated Inflammatory and Thermogenic Responses},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70053}
}
EUVIMED